Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.40 |
| ▸ | VCP | P55072 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.36 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2462099 | 0.99 | IGF1R (0.39) | IGF1RVCPALOX5SPHK1SPHK2 | |
| SCHEMBL2460471 | 0.88 | IGF1R (0.42) | IGF1RVCPALOX5HRH3NAAA | |
| SCHEMBL2464476 | 0.87 | IGF1R (0.41) | IGF1RVCPALOX5 | |
| SCHEMBL2460371 | 0.86 | NR1H2 (0.42) | NR1H2 | |
| SCHEMBL2456978 | 0.82 | MRGPRX4 (0.40) | NR1H2 | |
| SCHEMBL2459203 | 0.81 | NR1H2 (0.35) | IGF1RSPHK1SPHK2NR1H2 | |
| SCHEMBL2459990 | 0.81 | IGF1R (0.39) | IGF1RSPHK1SPHK2NR1H2 | |
| SCHEMBL2460369 | 0.80 | IGF1R (0.38) | IGF1RSPHK1SPHK2NR1H2 | |
| SCHEMBL2460381 | 0.79 | MAOB (0.38) | NR1H2 | |
| SCHEMBL2460621 | 0.79 | NR1H2 (0.39) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | disclosed |
| EP-1675860-A2 | IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | disclosed |
| WO-2005037836-A2 | IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885VCP 3998/4885ALOX5 4577/4885 |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885VCP 3998/4885ALOX5 4577/4885 |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885VCP 3998/4885ALOX5 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.